Form 4: 10x Genomics CFO Adam Taich Sells Shares for Tax Coverage
Statement of Changes in Beneficial Ownership
10x Genomics CFO Adam Taich sold 15,098 shares of Class A Common Stock to satisfy tax withholding obligations related to RSU vesting.
Summary
- CFO Adam Taich sold 15,098 shares of 10x Genomics (TXG) Class A Common Stock.
- The transaction occurred on May 22, 2026, at an average price of $24.4415 per share.
- The sale was executed to cover tax withholding obligations resulting from the vesting of restricted stock units (RSUs).
- Following this transaction, the reporting person retains beneficial ownership of 379,898 shares.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event, as the sale was purely administrative to cover tax liabilities rather than a discretionary divestment.
Positives
- The sale was non-discretionary, specifically executed to satisfy tax obligations associated with equity compensation vesting.
Negatives
- Reduction in the direct equity stake held by the Chief Financial Officer.
Risks
- None identified; this is a routine administrative transaction related to tax compliance.
Future Outlook
No forward-looking guidance or strategic outlook provided in this filing.
Management Comments
- The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units.
Industry Context
StockSavvy.ai notes that routine insider sales to cover tax obligations upon RSU vesting are standard corporate practice and generally do not signal a change in management sentiment regarding company performance.
Comparison to Industry Standards
- The transaction aligns with standard executive compensation practices in the biotechnology and life sciences sector.
- The sale is consistent with typical tax-related divestment patterns observed among C-suite executives at publicly traded firms.
Stakeholder Impact
- Minimal impact on shareholders as the sale was for tax compliance purposes.
Next Steps
- None indicated.
Key Dates
| Date | Description |
|---|---|
| 05/22/2026 | Date of the reported stock sale transaction. |
| 05/27/2026 | Date the Form 4 was signed and filed. |
Keywords
10x Genomics, TXG, Insider Trading, Form 4, CFO, Equity Vesting
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.